Aignostics Raises $34 Million Series B to Accelerate Precision Medicine with AI

Aignostics, a global leader in AI-powered pathology, announced the close of a $34 million Series B funding round to expand product offerings, strengthen its US presence, and co-develop foundation models for pathology in collaboration with Mayo Clinic.

The oversubscribed round was led by ATHOS, with participation from Mayo Clinic and HTGF, alongside returning investors Wellington Partners, Boehringer Ingelheim Venture Fund, CARMA Fund, and IBB Ventures. With this latest funding, Aignostics has now raised over $55 million.

The new capital will drive several strategic initiatives, including the development of "plug-and-play" solutions for tasks such as tumor microenvironment profiling and biomarker analysis.

Aignostics also plans to grow its U.S. operations, increasing headcount and deepening support for local partnerships. Additionally, the company will collaborate with Mayo Clinic to develop new foundation models for biopharma applications, furthering its product portfolio.

Aignostics leverages specialized AI foundation models for pathology, developed with a “pathologist-in-the-loop” approach to enhance accuracy, scalability, and real-world performance. Their platform integrates multimodal data, including histopathology, omics, and advanced modalities like spatial transcriptomics, to power solutions for target identification, translational research, and companion diagnostics. Unlike general-purpose LLMs, Aignostics’ foundation models are tailored for biomedical applications, streamlining biomarker analysis and drug development with minimal training data.

The company’s approach addresses the growing demand for AI in precision medicine, as biopharmaceutical companies seek scalable, high-performing tools to enhance pathology-based insights for drug discovery and diagnostics.

According to Viktor Matyas, CEO and co-founder, RudolfV (their foundation model) has enabled the company to create cost-efficient algorithms that generalize effectively to real-world applications.

Aignostics, founded in 2018 as a spin-off from Charité Berlin, combines proprietary multimodal clinical data with cutting-edge technologies to develop innovative solutions for precision medicine. They operate out of Berlin and New York.